ALS Drug Yields Meaningful Clinical Benefit, Phase 3 Data Show ALS Drug Yields Meaningful Clinical Benefit, Phase 3 Data Show
Longer-term data show the antisense oligonucleotide tofersen slows functional decline in patients with amyotrophic lateral sclerosis caused by superoxide dismutase 1 gene mutations.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 27, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Study Points to Jobs With Highest Risk for ALS
This study shows that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 26, 2022 Category: General Medicine Source Type: news
Occupational Exposures Tied to ALS Risk
FRIDAY, Sept. 23, 2022 -- Occupational exposures may increase the risk for amyotrophic lateral sclerosis (ALS), according to a study recently published in the International Archives of Occupational and Environmental Health.
Stephen A. Goutman,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 23, 2022 Category: Pharmaceuticals Source Type: news
Biogen drug slows progress of motor neurone disease in landmark trial
Tofersen targets a defective gene that causes about 2% of cases of MND, also known as amyotrophic lateral sclerosis (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 21, 2022 Category: Pharmaceuticals Source Type: news
Investigational ALS Drug Betters Biomarkers, but Can It Improve Motor Functions?
(MedPage Today) -- Tofersen, an investigational antisense oligonucleotide developed to treat an inherited form of amyotrophic lateral sclerosis (ALS), changed biomarkers and curbed neurodegeneration but did not improve motor control and muscle... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - September 21, 2022 Category: Neurology Source Type: news
In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in Second Review
THURSDAY, Sept. 8, 2022 -- In a rare second review, a U.S. Food and Drug Administration panel on Wednesday recommended approval for an experimental drug for amyotrophic lateral sclerosis (ALS). The FDA is not obligated to follow its advisers ' ... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 8, 2022 Category: Pharmaceuticals Source Type: news
In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in 2nd Review
THURSDAY, Sept. 8, 2022– In a rare second review, a U.S. Food and Drug Administration panel on Wednesday recommended approval for an experimental drug for ALS (amyotrophic lateral sclerosis).
The FDA is not obligated to follow its advisors ' ... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 8, 2022 Category: General Medicine Source Type: news
Controversial ALS Drug Gets Thumbs Up From FDA Advisors
(MedPage Today) -- In an unexpected reversal, an FDA advisory committee voted 7-2 on Wednesday to support approval of AMX0035, an investigational drug being evaluated for amyotrophic lateral sclerosis (ALS).
In late March, the same panel voted... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 8, 2022 Category: American Health Source Type: news
Blood Test Shows Promise for Quick Diagnosis of ALS
WEDNESDAY, Sept. 7, 2022 -- Patients suspected of having amyotrophic lateral sclerosis (ALS) may soon be able to get a diagnosis much more quickly, not wasting the precious time many have left, new research suggests.
In 2020, a blood test for ALS... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 7, 2022 Category: General Medicine Source Type: news
FDA Panel Skeptical of Controversial ALS Drug Ahead of Vote
TUESDAY, Sept. 6, 2022 -- A U.S. Food and Drug Administration panel will once again consider approval for an experimental drug for amyotrophic lateral sclerosis (ALS), a rare second review for a disease that has no cure.
The same panel that will... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 6, 2022 Category: Pharmaceuticals Source Type: news
More FDA Skepticism for ALS Drug Second Time Around
(MedPage Today) -- Even with new data, FDA reviewers remain skeptical about AMX0035, the investigational drug for amyotrophic lateral sclerosis (ALS) getting a rare second chance before an FDA advisory committee on Wednesday.
Post hoc analyses... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 6, 2022 Category: American Health Source Type: news
Stem cell-gene therapy shows promise in ALS safety trial
Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This combined stem cell and gene therapy can potentially protect diseased motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis, a fatal neurological disorder known as ALS or Lou Gehrig's disease. (Source: World Pharma News)
Source: World Pharma News - September 5, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Mutant T Cells That Drive Amyotrophic Lateral Sclerosis (ALS) Progression May React To a Brain Antigen
Scientists discovered a possibly autoreactive T cell population that forecasts and supports disease progression. (Source: The Scientist)
Source: The Scientist - August 8, 2022 Category: Science Tags: Sponsored Article Source Type: news
The Petri Dish: FDA agrees to review Biogen's ALS drug despite failed trial
The FDA has granted priority review to tofersen, a drug for a certain genetic form of amyotrophic lateral sclerosis. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 28, 2022 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
US FDA to Reconvene Experts' Meeting for Amylyx ALS Drug US FDA to Reconvene Experts' Meeting for Amylyx ALS Drug
The US Food and Drug Administration will reconvene a meeting of its outside experts to review Amylyx Pharmaceuticals ' application for its amyotrophic lateral sclerosis treatment, the company said Tuesday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
